“Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial” (2022) SKIN The Journal of Cutaneous Medicine, 6(2), p. s29. doi:10.25251/skin.6.supp.s29.